Diroximel fumarate primarily functions by the modulation of the immune system and prevention of inflammation, both of which are at the core of the cause of multiple sclerosis (MS) formation. MS is the process of the immune system’s attack on the sheath of the nerve cells in the central nervous system. It can inhibit the inflammation process in various ways and thus prevent further nerve damage and shorten disease formation.
Activates Nrf2 Pathway: Diroximel fumarate increases the effectiveness of protein Nrf2, which defends cells against oxidative stress and inflammation. The pathway decreases damage from the immune attack on the nerve cells.
Modulates Immune Response: By modulating the immune system, Diroximel fumarate lowers the frequency of immune cell attacks leading to damage in nerves and new lesions, or plaques, on the brain and spinal cord.
Reduces Inflammation: It also reduces the rate of pro-inflammatory molecules, thereby calming the entire inflammatory process associated with MS.
Just like any medication, Diroximel fumarate has side effects, but not everyone experiences them.
Common Side Effects:
Flushing: A side effect in which the skin is red, warm, or flushed, typically on the face.
Gastrointestinal Symptoms: The patients are nauseated, have diarrhea, stomachache, or indigestion but milder than in other fumarate drugs.
Headache: The patients also have headaches at the start of the therapy.
Serious Side Effects:
Liver Issues: Diroximel fumarate may lead to liver damage, and therefore liver function is crucial in a patient taking this medication. Liver disease is signaled by yellow skin or eyes (jaundice), dark urine, and unexplained fatigue.
Low White Blood Cell Count: It may result in a low white blood cell count, which could raise the risk of infection.
Allergic Reactions: While rare, some patients can become allergic to Diroximel fumarate, and the reaction can be rash, itching, or shortness of breath.
PML (Progressive Multifocal Leukoencephalopathy): Rare but serious viral encephalopathy in immunocompromised patients. PML is an immune-mediated central nervous system inflammatory demyelinating disease in immunomodulatory patients. It is among the immunomodulatory therapy patient’s risk factors.
Diroximel fumarate is a prescription medication, which means it should be prescribed and monitored by a healthcare provider. It is important to discuss your medical history, including any liver issues, allergies, or current medications, with your healthcare provider before starting treatment.